Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. 1978

R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone

One hundred and sixty-five patients with advanced renal cell cancer were evaluable for combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone. A low order or response was observed, and these agents were not proven effective as treatment for metastatic renal cell cancer. Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease were found to be the most prognostically significant factors for survival.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
January 1981, Cancer treatment reports,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
January 1985, Cancer chemotherapy and pharmacology,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
March 1976, Cancer treatment reports,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
September 1979, Cancer,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
September 1982, Cancer treatment reports,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
January 1975, The Journal of urology,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
January 1994, European journal of cancer (Oxford, England : 1990),
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
November 1976, Cancer treatment reports,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
August 1990, Journal of biological response modifiers,
R G Hahn, and N R Temkin, and E D Savlov, and C Perlia, and G L Wampler, and J Horton, and J Marsh, and P P Carbone
August 1989, The Journal of urology,
Copied contents to your clipboard!